Injectable
Triptorelin pamoate RTU
1.875 mg/mL · Ready-to-use injection · Advanced prostate cancer (palliative)
Product data
- Strength
- 1.875 mg/mL
- Dosage form
- Ready-to-use injection
- Dosage-form group
- Injectable
- Therapeutic area
- Advanced prostate cancer (palliative)
- Status
- Under development
- Portfolio
- Injectable
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23